摘要
鞘氨醇激酶1(Sphk1)是维持细胞内鞘脂平衡的关键限速酶与细胞内信号转导酶,维持鞘氨醇-1-磷酸、神经酰胺和鞘氨醇的平衡,参与调节细胞增殖与凋亡、血管收缩与重塑、炎症与代谢等多种生理功能。本文综述近10年来Sphk1的相关研究,以期为癌症和肺动脉高压治疗药物的研发奠定基础。
Sphingosine kinase -1 ( Sphk1) is a crucial rate - limiting en- zyme and signal transduction enzyme. Sphk1 maintains the balance of sphingosine -1 - phosphate,ceramide and sphingosine,and participats in the modulation of cell proliferation and apoptosis,vasoconstriction and remodeling,inflammation and metabolism. This article reviews the researches on Sphk1 in the past one decade,hoping to provide a better understanding for novel drugs development in the therapy for pulmonary hypertension and cancer targeting Sphk1.
作者
曹辉
任欢欢
林风越
牛征
姚丽
CAO Hui;REN Huan-huan;LIN Feng-yue;NIU Zheng;YAO Li(Department of Medical Chemistry and Pharmaceutical Chemistry, Harbin Medical University,College of Pharmacy, Harbin 150081,Heilongjiang Province, China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第15期1706-1708,共3页
The Chinese Journal of Clinical Pharmacology
基金
国家自然科学基金资助项目(NO.81302764)
哈尔滨市科技创新人才研究专项基金资助项目(2017RAXXJ060)
黑龙江省中医药管理局基金资助项目(NO.GHY10-Z99)
关键词
鞘氨醇激酶1
癌症
肺动脉高压
炎症
Sphingosine kinase 1
cancer
pulmonary hypertension
inflammation
